NKG2D blockade attenuates CD8⁺ T cell–mediated GVHD. (A) Irradiated Balb/c mice were transplanted with B6-derived TCD BM alone or with B6-derived TCD BM cells and FACS-sorted CD8⁺ T cells. The mice were treated 3 times per week with either isotype control antibody (IgG) or anti-NKG2D antibody for 2 weeks. (B) Irradiated Balb/c mice were transplanted with B6-derived TCD BM alone or with B6-derived TCD BM cells and B6-derived or NKG2D KO-derived FACS-sorted CD8⁺ T cells. (C) Irradiated B6 mice were transplanted with C3H.SW-derived TCD BM alone or with B6-derived TCD BM cells and FACS-sorted CD8⁺ T cells. The mice were treated 3 times per week with either isotype control antibody (IgG) or anti-NKG2D antibody for 2 weeks. The mice were monitored for survival (left), body weight changes (middle), and clinical score (right) for 40 days post-BMT. The survival graph was generated using all mice from 2 or 3 independent experiments (n = 3-5 mice/group per experiment). One representative of 2 or 3 independent experiments is shown for weight changes and clinical score (n = 3-4 mice/group). Statistical analysis for survival was performed using the log-rank test.